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Cervical cancer elimination through human papillomavirus (HPV) vaccination programs
requires the attainment of herd effect. Due to its uniquely high basic reproduction number,
the vaccination coverage required to achieve herd effect against HPV type 16 exceeds what
is attainable in most populations. We have compared how gender-neutral and girls-only vac-
cination strategies create herd effect against HPV16 under moderate vaccination coverage
achieved in a population-based, community-randomized trial.
Methods and findings
In 2007–2010, the 1992–1995 birth cohorts of 33 Finnish communities were randomized to
receive gender-neutral HPV vaccination (Arm A), girls-only HPV vaccination (Arm B), or no
HPV vaccination (Arm C) (11 communities per trial arm). HPV16/18/31/33/35/45 seropreva-
lence differences between the pre-vaccination era (2005–2010) and post-vaccination era
(2011–2016) were compared between all 8,022 unvaccinated women <23 years old and
resident in the 33 communities during 2005–2016 (2,657, 2,691, and 2,674 in Arms A, B,
and C, respectively). Post- versus pre-vaccination-era HPV seroprevalence ratios (PRs)
were compared by arm. Possible outcome misclassification was quantified via probabilistic
bias analysis. An HPV16 and HPV18 seroprevalence reduction was observed post-
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vaccination in the gender-neutral vaccination arm in the entire study population (PR16 =
0.64, 95% CI 0.10–0.85; PR18 = 0.72, 95% CI 0.22–0.96) and for HPV16 also in the herpes
simplex virus type 2 seropositive core group (PR16 = 0.64, 95% CI 0.50–0.81). Observed
reductions in HPV31/33/35/45 seroprevalence (PR31/33/35/45 = 0.88, 95% CI 0.81–0.97)
were replicated in Arm C (PR31/33/35/45 = 0.79, 95% CI 0.69–0.90).
Conclusions
In this study we only observed herd effect against HPV16/18 after gender-neutral vaccina-
tion with moderate vaccination coverage. With only moderate vaccination coverage, a gen-
der-neutral vaccination strategy can facilitate the control of even HPV16. Our findings may
have limited transportability to other vaccination coverage levels.
Trial registration
ClinicalTrials.gov number NCT00534638, https://clinicaltrials.gov/ct2/show/NCT00534638.
Author summary
Why was this study done?
• High-risk human papillomavirus (HPV) infection is a necessary cause of cervical cancer
in females.
• HPV vaccination targeting high-risk HPV types 16 and 18 has been implemented
internationally.
• Achieving herd protection for HPV16 may require greater than 80% girls-only vaccina-
tion coverage, a level that has not been achievable in many countries.
• We evaluate whether gender-neutral or girls-only HPV vaccination results in HPV16
and HPV18 herd protection when the vaccination coverage is only moderate (40%–
50%).
What did the researchers do and find?
• We implemented a community-randomized trial of gender-neutral versus girls-only
versus no HPV vaccination of young adolescents in 2007–2010, with 11 communities in
each arm. Vaccination coverage was implemented with moderate coverage (40%–50%)
at the community level.
• We evaluated the herd effect created by the different vaccination strategies by measuring
the cumulative incidence of vaccine-protected HPV types in 8,022 young unvaccinated
pregnant females (under 23 years old), comparing the time periods 2005–2010 (pre-vac-
cination) and 2011–2016 (post-vaccination).
• An HPV16 herd effect, that is, a reduction in cumulative incidence among the unvacci-
nated females, was only observed in communities where gender-neutral vaccination
had been implemented.
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What do these findings mean?
• Achieving a vaccination coverage of above 80%, which is required to achieve herd effect
against HPV16, may be unrealistic in some populations. Implementing gender-neutral
HPV vaccination provides a solution to this problem as the vaccination coverage thresh-
old required to provide herd effect to unvaccinated females is lower.
• Our study finds that gender-neutral vaccination provides stronger herd effect than girls-
only vaccination in the setting of moderate vaccination coverage. However, these find-
ings are limited to this setting and are not readily generalizable to settings with high
(>80%) vaccination coverage.
Introduction
The World Health Organization has called for the elimination of cervical cancer as a public
health problem [1]. To this end, the WHO has developed a global strategy requiring every
country globally to achieve 90% human papillomavirus (HPV) vaccination of girls by the age
of 15 years by the year 2030 [2]. However, although some countries such as Scotland have
achieved 90% coverage, achieving this globally may be a near impossible challenge [3,4]. Pres-
ent vaccination coverage levels [5] are notably below the 80% vaccination coverage that is
required for the eradication of vaccine-targeted HPV types [6], and herd effect among unvacci-
nated individuals is needed.
HPV vaccines provide not only strong direct protection but also herd effect/herd protec-
tion, also known as herd immunity (i.e., indirect protection to unvaccinated individuals) due
to assortative transmission of the HPVs [7–10]. Modeling studies have suggested that already
low to moderate vaccination coverage inclusion of boys provides incremental herd effect to
unvaccinated girls [6,9,11,12]. In our unique community-randomized HPV16/18 vaccination
trial, the herd effect/herd immunity created has been measured as the degree of decrease in
HPV incidence/prevalence in unvaccinated women [7,13,14]. We found the predicted herd
effect against vaccine-targeted HPV18, and cross-protection against HPV types 31, 33, 35, and
45, when vaccination coverage was approximately 50% [7,13,14]. In populations implementing
girls-only vaccination, notable herd effect against HPV16 (the most oncogenic and most com-
mon HPV type) has only been observed when the vaccination coverage was high [15–17]. This
is probably due to the high basic reproduction number (R0) of HPV16 compared to other
HPV types [17], and may depend also on the method of identifying HPV occurrence (one-
time PCR positivity or seropositivity, i.e., prevalence or cumulative incidence).
We performed population-based HPV analysis to evaluate the herd effect created by gen-
der-neutral or girls-only vaccination following our community-randomized trial in the
instance of low to moderate vaccination coverage. In the previous reports of this trial, the herd
effect was evaluated using transitory HPV PCR positivity in study participants when they were
aged 18 and/or 22 years; although notable HPV18 herd effect was observed, no HPV16 herd
effect was found [12,13,18]. To provide assurance that the lack of HPV16 herd effect was not
due to the methodological approach, we then nested a cross-sectional cohort within the com-
munity-randomized trial. We then estimated HPV16 seroprevalence (cumulative HPV16 inci-
dence) over time using pre-and post-vaccination-era sera from unvaccinated women under
the age of 23 years and resident in the communities with gender-neutral or girls-only vaccina-
tion strategies. Possible clearance of an ecological niche by HPV16/18 vaccination is also now
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described as the natural counterpart to the serology-based type-replacement study concerning
non-vaccine HPV types [18].
Methods
Study design
A population-based, community-randomized HPV vaccination trial was conducted among
female and male 1992–1995 birth cohorts between 2007 and 2010 [19]. The trial was originally
designed to guide evidence-based decision-making regarding national HPV vaccination policy
[20,21], by testing the primary hypothesis of difference in the creation of herd effect by gen-
der-neutral versus girls-only HPV vaccination strategies. Thirty-three geographically distinct
Finnish communities located a minimum of 50 km from the next nearest community (or 35
km in the case of the 5 communities from the Helsinki metropolitan area) were included in
the trial. To increase study power, the coefficient of variation, Ks (Ks = 0.13), between commu-
nities was minimized by first stratifying the communities by previously ascertained HPV16/18
seroprevalence [22] into those with low, moderate, and high seroprevalence. From these 3
strata, the communities were then randomized using a random number generator to 3 trial
arms: In Arm A communities, 90% of girls and boys received HPV vaccination, and 10% of
girls and boys received hepatitis B virus (HBV) vaccination; in Arm B communities, 90% of
girls received HPV vaccination, and 10% of girls and all boys received HBV vaccination; in
Arm C communities, all girls and boys received HBV vaccination.
In total, 80,272 Finnish- or Swedish-speaking girls and boys in the 1992–1995 birth cohorts
were identified via the Finnish Population Register Centre as being resident in the 33 trial
communities. Out of this group, 20,513 girls and 11,662 boys participated in the trial with
parental/guardian informed consent. The study was partially blinded to all Arm A study par-
ticipants and all female Arm B participants. Vaccination took place from 2007 to 2010, when
the participants were aged 12–15 years, with 99.4% of participants receiving all 3 doses of the
allocated vaccine (the bivalent HPV vaccine Cervarix or the HBV vaccine Engerix-B). The
mean community-level vaccination coverage acquired via this vaccination was 47.1% in Arm
A communities and 45.8% in Arm B communities among girls from the 1992–1995 birth
cohorts (standard deviation [SD] = 9.4% and 6.6%, respectively). In Arm A communities the
vaccination coverage acquired among boys from the 1992–1995 birth cohorts was 19.5%
(SD = 7.1%) [19,20].
The creation of herd effect by different HPV16/18 vaccination strategies over time was esti-
mated via a nested cross-sectional cohort study [23] of all pregnant women under the age of 23
years who were resident in the 33 trial communities from 2005 until the end of 2016. Their
serum samples were extracted from a population-representative biobank, the Finnish Mater-
nity Cohort (FMC) [18,21]. The FMC biobank houses 2 million serum samples obtained from
approximately all 1 million pregnant Finnish women between 1983 and 2016 for screening of
congenital infections. The participating women provided informed consent at the maternity
clinic to have their samples stored for research purposes by the FMC biobank; 96% of women
consented.
FMC participants eligible for this study were under the age of 23 years at the time of sample
donation, first-time donators to the FMC, resident in 1 of the 33 trial communities, and HPV
unvaccinated [18]. In Finland, every citizen (or person resident for greater than 3 months) is
given a unique personal identification number at birth (or shortly after arrival into the coun-
try). HPV vaccination status was confirmed by linkage via the participants personal identifica-
tion number with the national HPV vaccination trial registry both prior to and after sample
extraction. For the birth cohorts eligible to receive HPV vaccination via the Finnish national
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vaccination program (1998 and younger birth cohorts), HPV vaccination status was ascer-
tained by manually scrutinizing participants’ HPV antibody levels for titers indicative of HPV
vaccination (i.e., multiple-fold those acquired via natural infection for HPV16 and HPV18).
The eligible participants for the serosurvey came from the 1982 and younger birth cohorts.
The 1992 to 1995 birth cohorts were exposed to community-level vaccination via the commu-
nity-randomized trial intervention, and the 1998 and younger birth cohorts were exposed to
community-level HPV vaccination via the Finnish national HPV vaccination program initi-
ated in late 2013 (Fig 1 and S1 Fig). The sampling time frame was divided into the pre-vaccina-
tion period (2005–2010) and the post-vaccination period (2011–2016). All the pregnant
females under the age of 23 years at the time of sample donation from each of the trial commu-
nities were included, totaling 8,022 females.
Data regarding self-reported maternal smoking among women under the age of 23 years
and resident in the 33 communities between 2005 and 2016 were collected from the Finnish
Medical Birth Register, and used as a surrogate of community-level risk-taking behaviors. To
define the core group with high contact rate, we identified herpes simplex virus type 2 (HSV-
2) seropositive women [18]. Data on community-specific vaccination coverage over each
calendar year were collected from the HPV trial registry for the birth cohorts exposed to the
community-randomized trial and from the Finnish vaccination register for the birth cohorts
exposed to the Finnish national HPV vaccination program.
This study is reported in accordance to the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) guideline (S1 Checklist).
Ethics
The community-randomized HPV-040 study obtained permissions from the Ethical Review
Board of Pirkanmaa Hospital District (R07113M 14.6.2007). The FMC steering committee
Fig 1. Lexis diagrams depicting the community-level exposure of the adolescent population to direct and indirect effects of the
cluster-randomized human papillomavirus vaccination trial by birth cohort and study arm. hite bars represent the birth cohorts
with no vaccination, and the purple (trial vaccination) and orange (national vaccination) bars represent post-vaccination birth cohorts.
The blue dashed lines indicate the sampling years and ages of this study. The colored fill of the symbols indicates the proportion of each
type of vaccination that took place at that time point and age per birth cohort.
https://doi.org/10.1371/journal.pmed.1003588.g001
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granted permission for the linkage and use of the serum samples. No harm was caused to the
cohorts.
Laboratory analyses
The serum samples were analyzed for the presence of IgG antibodies to HPV types 6, 11, 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 73 and HSV-2 using multiplexed heparin-
bound pseudovirion (and HSV-2 glycoprotein gG2) Luminex assay [24]. Seropositivity cutoff
levels were established with a negative control panel of serum samples from 191 children�12
years old (mean age = 4.7 years) (S1 Text).
Statistical analyses
The primary hypothesis of this study was that HPV16/18 vaccination created a herd effect (in
the HPV-040 and type-replacement study protocols, this was called “indirect effect” or “eco-
logical niche formation”) over time. In this study, herd effect is defined and measured as the
degree of decrease in HPV cumulative incidence (unattributable to random or systematic
error) among unvaccinated individuals in the post-vaccination era. To investigate the herd
effect (indirect effect) of increasing community-level HPV16/18 vaccination during the study
period (via a gender-neutral or girls-only vaccination strategy), we calculated the absolute
seroprevalence of vaccine-targeted HPV types 16, 18, and 16/18 (combined), and vaccine-
cross-protected HPV types 31, 33, 35, 45, and 31/33/35/45 (combined). This was calculated for
the pre- and post-vaccination eras, 2005–2010 and 2011–2016, respectively. In the case of the
former, the participants who had donated the sera were likely to have been unexposed to the
indirect effects of HPV vaccination, whereas in the case of the latter, the participants may have
been under herd effect [14,19,20].
The degree of clustering of HPV16/18 and HPV16/18/31/33/35/45 seropositivity was
assessed by calculation of the intracluster correlation coefficient from the pre-vaccination-era
data (from 2005 to 2010) using Fleiss and Cuzick’s estimator in combination with Zou and
Donner’s modified Wald test to compute the 95% confidence intervals [25,26].
The exposure in this study is defined as exposure to the herd effects (indirect effects) of
HPV16/18 vaccination due to residing at the time of sample donation in one of the communi-
ties of the community-randomized trial. Thus, to evaluate the extent of exposure in the study
population of pregnant females under the age of 23 years, the birth-cohort-, community-, and
year-specific vaccination coverage was calculated. From this, the community-specific vaccina-
tion coverage by year among the study population was then calculated as the birth-cohort-
weighted vaccination coverage by gender, weighted by the proportion of participants from
each birth cohort found in each year of the study among the study population of pregnant
females. We also calculated HSV-2 seroprevalence to assess changes in the occurrence of sexu-
ally transmitted infections between the pre- and post-vaccination eras. Calendar-time-specific
absolute seroprevalence was calculated stratified by Arms A, B, and C of the community-ran-
domized trial. The accompanying 95% confidence intervals were calculated using the Agresti–
Coull method [27].
To further assess the indirect effect of community-level vaccination in the post-vaccination
era, we estimated within-arm seroprevalence ratios (PRs) comparing the post- to pre-vaccina-
tion HPV-type-specific seroprevalence (for HPV types 16, 18, 31, 33, 35, 45, and 16/18 com-
bined) using a log binomial generalized estimating equation (GEE) model to take account of
within-arm clustering. HPV-type-specific seroprevalence was not directly compared between
the arms as stated in the pre-analysis plan (S2 Text), as statistically significant differences were
found between the arms at baseline prior to any HPV vaccination. To take account of possible
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confounding, all estimates were adjusted for community-level self-reported maternal smoking,
as a surrogate of community-level risk-taking behaviors. To investigate the effect of core group
membership (a possible effect modifier) on the indirect effect, the secondary outcome of the
study, we stratified the estimates by HSV-2 seropositivity.
To estimate the overall herd effect (the indirect effect) of gender-neutral and girls-only
HPV vaccination compared to the counterfactual scenario, we further calculated the between-
arm ratio of PRs, comparing the within-arm PR (adjusted for community-level maternal
smoking) of Arm A or B (the intervention arms) to the PR of the control Arm C. The accom-
panying 95% confidence intervals were calculated according to the methodology of Altman
and Bland [28].
Systematic outcome misclassification of the serological assay was quantified and corrected
for assuming non-differential bias of the within- and between-arm estimates via probabilistic
bias analysis [29]. Previously obtained estimates of test sensitivity and specificity were used at
the outset (S1 Table) [30], assuming a constant probability distribution. If these prior estimates
proved incompatible with the observed data, then a uniform probability density ranging from
0 to 1 was specified, to obtain all plausible values of the sensitivity or specificity compatible
with the observed data. The resultant range of plausible values for the given HPV-type-specific
sensitivity or specificity was then assumed, with a uniform probability density ranging from
the given minimum to maximum value. The results from this sensitivity analysis were then
used to quantify misclassification in the primary analysis.
All statistical analyses were conducted using the R statistical software package (version
3.6.0.).
Results
Baseline characteristics of the study population
In total, all 8,022 HPV-unvaccinated pregnant females under the age of 23 years who were
resident in one of the 33 trial communities and had been invited to donate a blood sample to
the FMC between the years 2005 and 2016 were identified. An additional 3,498 females were
initially found to be ineligible due to being HPV vaccinated. In total, 4,007 participants were
from the era preceding completion of vaccination (2005–2010), and 4,015 were from the
post-vaccination era (2011–2016). Participants were excluded from the statistical analyses
owing to HPV vaccination (N = 49) or being aged >22 years at sample donation (N = 436).
In total, 7,531 women were included: 1,322, 1,289, and 1,304 from the pre-vaccination-era
Arm A, B, and C communities, respectively, and 1,247, 1,158, and 1,211 from the same post-
vaccination-era communities (Fig 2). The intracluster correlation coefficient was consis-
tently low, at 0.007 for HPV16/18 seropositivity and 0.005 for HPV16/18/31/33/35/45 sero-
positivity (S2 Table).
The participants’ age distributions in the pre-vaccination and post-vaccination eras were
comparable, with the majority being 18 to 22 years old (S3 Table). The HSV-2 seroprevalence
was materially similar between the arms, but somewhat higher in the pre-vaccination era as
compared to the post-vaccination era (17.8% and 15.0%, respectively) (Fig 3). Community-
level self-reported smoking was consistently higher in the control Arm C communities than in
the gender-neutral vaccination Arm A and girls-only vaccination Arm B communities (S3
Table). The community-specific vaccination coverage among the eligible female birth cohorts
for this study was negligible in the pre-vaccination era, from 2005 until 2010, and increased in
the post-vaccination era in the intervention arm communities (from 5.6% to 52.5% in Arm A,
and from 6.3% to 46.7% in Arm B) (Fig 4).
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HPV seroprevalence by vaccination era
In the pre-vaccination era, HPV16/18 seroprevalence was high: 29.7%, 29.6%, and 26.8%,
respectively, in the Arm A, B, and C communities. In the post-vaccination era, HPV16/18
seroprevalence was somewhat decreased (23.6%) in the gender-neutral vaccination Arm A
Fig 2. Flow chart of the cross-sectional cohort study nested in the Finnish community randomized human
papillomavirus (HPV) vaccination trial with stepwise subsequent exclusions. 1The arms are the trial arms from the
cluster (community) randomized trial of HPV vaccination strategy, conducted in 2007–2010.2Includes all females aged
3–22 years who were resident in the communities specified as of the 31 December 2005 (data extracted from Statistics
Finland).
https://doi.org/10.1371/journal.pmed.1003588.g002
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communities (Fig 3; S4 Table). Notably, the HPV16 seroprevalence was decreased in the Arm
A communities in the post-vaccination era compared to the pre-vaccination era (17.4% versus
22.1%). No decrease in HPV16 seroprevalence was noted in the girls-only vaccination Arm B
or control C communities (Fig 3; S4 Table).
Within-arm post- versus pre-vaccination-era HPV PRs
The within-arm HPV16/18 PR comparing the post- to the pre-vaccination era was notably
decreased in Arm A. The HPV16/18 estimate was significantly somewhat decreased in the gen-
der-neutral vaccination Arm A (PR16/18 = 0.80, 95% CI 0.74–0.87), whereas in the girls-only
vaccination Arm B and control Arm C, no significant reductions were noted (PR16/18 = 0.98,
Fig 3. Type-specific human papillomavirus (HPV) and herpes simplex virus type 2 (HSV-2) seroprevalence (%) among unvaccinated females under
the age of 23 years by intervention strategy: Gender-neutral vaccination (Arm A), girls-only vaccination (Arm B), and control vaccination (Arm C).
Type-specific seroprevalence is stratified by time period of sample donation (pre-vaccination era, 2005–2010; post-vaccination era, 2011–2016).
https://doi.org/10.1371/journal.pmed.1003588.g003
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95% CI 0.85–1.12, in Arm B; PR16/18 = 0.91, 95% CI 0.81–1.03, in Arm C) (Table 1). The
HPV16 PR specifically was decreased in Arm A (PR16 = 0.79, 95% CI 0.72–0.87). No corre-
sponding decrease was observed in Arms B or C (PR16 = 1.09, 95% CI 0.91–1.32, in Arm B;
PR16 = 1.01, 95% CI 0.86–1.20, in Arm C) (Table 1). After applying probabilistic bias analysis
to correct for outcome misclassification, the within-arm HPV16/18 and HPV16 PR estimates
in Arm A were found to be further decreased (PR16/18 = 0.66, 95% CI 0.10–0.85, and PR16 =
0.64, 95% CI 0.09–0.86, respectively). Also, the within-arm PR estimate for HPV18 was signifi-
cantly decreased in the gender-neutral vaccination Arm A after accounting for the error due to
outcome misclassification (PR18 = 0.72, 95% CI 0.21–0.96) (Table 1).
Fig 4. Evaluation of human papillomavirus (HPV) vaccination coverage in the study population: Community-
specific birth-cohort-weighted vaccination coverage of the consecutive community-randomized trial and national
girls-only vaccination program. Exposure to the indirect effects of HPV16/18 vaccination is defined as residing at the
time of sample donation in one of the community-randomized HPV vaccination trial communities. Each row
represents a trial community, and each column a year of the follow-up period. The community-specific vaccination
coverage is calculated for pregnant females under the age of 23 years and includes vaccination of 12- to 15-year-old
males and females in 2007–2010, and the national girls-only vaccination program launched in late 2013.
https://doi.org/10.1371/journal.pmed.1003588.g004
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The HPV35 PR estimate was significantly decreased in the gender-neutral vaccination Arm
A (PR35 = 0.70, 95% CI 0.52–0.94; Table 1). However, this finding appeared to be essentially
replicated in the control Arm C (PR35 = 0.77, 95% CI 0.58–1.01; Table 1). No decrease in
HPV35 seroprevalence was observed in the girls-only vaccination Arm B (PR35 = 0.98, 95% CI
0.64–1.51). HPV31 was non-significantly slightly decreased in both the gender-neutral vacci-
nation Arm A and the girls-only vaccination Arm B (PR31 = 0.90, 95% CI 0.79–1.01, in Arm A;
PR31 = 0.86, 95% CI 0.73–1.02, in Arm B), but was further decreased in the control Arm C
with no HPV vaccination (PR31 = 0.72, 95% CI 0.57–0.91). HPV33 was not decreased in Arm
A (PR33 = 1.05, 95% CI 0.88–1.26), while it approximately stayed the same in Arm B (PR33 =
0.94, 95% CI 0.77–1.14) and non-significantly decreased slightly in Arm C (PR33 = 0.81, 95%
CI 0.63–1.03). On the other hand, HPV45 was non-significantly marginally decreased in Arm
A (PR45 = 0.89, 95% CI 0.69–1.14), approximated the null in Arm B (PR45 = 1.01, 95% CI
0.76–1.36), and in Arm C was decreased in a similar manner as in Arm A (PR45 = 0.90, 95% CI
0.64–1.26) (Table 1).
The HPV16 PR estimate was also noticeably decreased among the HSV-2 seropositive indi-
viduals in the gender-neutral vaccination Arm A (PR16 = 0.64, 95% CI 0.50–0.81). Most esti-
mates for vaccine-protected HPV types were also decreased among the HSV-2 seropositive
individuals, especially in Arm A (PR31 = 0.74, 95% CI 0.53–1.02; PR35 = 0.57, 95% CI 0.37–
0.88; PR45 = 0.64, 95% CI 0.37–1.08), albeit sometimes with borderline statistical significance.
The findings for HPV31 and HPV45 were, however, replicated in the control Arm C (PR31 =
0.64, 95% CI 0.42–0.98; PR45 = 0.69, 95% CI 0.37–1.30) (S6 Table).
Table 1. Post- versus pre-vaccination HPV-type-specific adjusted seroprevalence ratio (PR) among unvaccinated
Finnish females aged under 23 years.
HPV type Post- versus pre-vaccination-era PR (95% CI)
Arm A (N = 1,247 versus 1,322) Arm B (N = 1,158 versus 1,289) Arm C (N = 1,211 versus 1,304)
Accounting for random error
16 0.79 (0.72–0.87) 1.09 (0.91–1.32) 1.01 (0.86–1.20)
18 0.86 (0.70–1.06) 0.96 (0.74–1.24) 0.89 (0.70–1.13)
16/18 0.80 (0.74–0.87) 0.98 (0.85–1.12) 0.91 (0.81–1.03)
31 0.90 (0.79–1.01) 0.86 (0.73–1.02) 0.72 (0.57–0.91)
33 1.05 (0.88–1.26) 0.94 (0.77–1.14) 0.81 (0.63–1.03)
35 0.70 (0.52–0.94) 0.98 (0.64–1.51) 0.77 (0.58–1.01)
45 0.89 (0.69–1.14) 1.01 (0.76–1.36) 0.90 (0.64–1.26)
Accounting for random error and systematic error
16 0.64 (0.09–0.86) 1.19 (0.98–3.70) 1.07 (0.89–1.85)
18 0.72 (0.21–0.96) 0.89 (0.39–1.12) 0.79 (0.21–1.03)
16/18 0.66 (0.10–0.85) 0.92 (0.44–1.07) 0.84 (0.24–1.01)
31 0.79 (0.20–1.00) 0.75 (0.15–0.97) 0.55 (0.07–0.78)
33 1.14 (0.86–2.73) 0.85 (0.31–1.13) 0.66 (0.15–0.94)
35 0.52 (0.07–0.83) 0.90 (0.44–1.25) 0.59 (0.10–0.91)
45 0.73 (0.19–1.06) 1.01 (0.78–1.33) 0.79 (0.25–1.13)
Comparisons are between 2 time periods of sample donation (2011–2016, post-vaccination era, versus 2005–2010,
pre-vaccination era), stratified by intervention Arm A (gender-neutral HPV vaccination), Arm B (girls-only HPV
vaccination), and Arm C (control vaccination), accounting for random error and accounting for random error and
systematic error due to outcome misclassification. The estimates corrected for random error only are adjusted for
community-level smoking. Corresponding unadjusted estimates are displayed in S5 Table.
https://doi.org/10.1371/journal.pmed.1003588.t001
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Between-arm comparison of the post- versus pre-vaccination-era PRs
To account for possible secular trends, between-arm comparisons of the within-arm post- ver-
sus pre-vaccination-era PRs were made, comparing the ratios from HPV vaccination arms to
the ratios from the control Arm C. The HPV16 ratio of PRs (RPR), remained decreased when
comparing the gender-neutral vaccination Arm A to the control Arm C (RPR16 = 0.78, 95% CI
0.64–0.95) (Fig 5).
Discussion
We nested a cross-sectional cohort within a population-based, community-randomized
HPV16/18 vaccination trial to estimate changes over time in HPV16/18 seroprevalence created
by gender-neutral or girls-only vaccination strategies, using pre- and post-vaccination-era sera
from unvaccinated women resident in the trial communities. The HPV16 and HPV18 sero-
prevalence was somewhat decreased in young unvaccinated women after gender-neutral vacci-
nation. This was observed although the vaccination coverage was only moderate to low. Most
importantly, a degree of partial herd effect against HPV16 was observed over time within the
gender-neutral vaccination arm, when compared to the counterfactual control arm, and within
the HSV-2 seropositive core group, representing those with high contact rate. Girls-only HPV
Fig 5. Ratio of human papillomavirus (HPV) seroprevalence ratios (PRs) comparing Arm A/B to Arm C. Arm-specific PRs comprise post-
vaccination to pre-vaccination-era HPV PRs among pregnant unvaccinated Finnish females, aged under 23 years, and adjusted for community-
level maternal smoking. RPR, ratio of seroprevalence ratios.
https://doi.org/10.1371/journal.pmed.1003588.g005
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vaccination with moderate vaccination coverage did not result in any notable HPV16 herd
effect.
The level of vaccination coverage required for herd effect is a function of a given HPV
type’s basic reproduction number. This in turn is a function of the effective transmission rate
and the mean duration of infection, which for HPV16 is especially long. Thus, the vaccination
coverage required to achieve herd effect against HPV16 is expected to be high, higher than for
other HPV types [14], and for girls-only vaccination this indeed seems to be the case [16]. Fur-
thermore, the predicted herd effect is 25% to 50% greater for a gender-neutral than for a girls-
only vaccination scenario [23]. Our study provides empirical evidence that when vaccination
coverage is suboptimal, a gender-neutral vaccination strategy optimizes HPV16 herd effect
and thus effectiveness of vaccination.
This observation is of major importance, if the call for action to eliminate cervical cancer is
realistically going to be achieved. The gender-neutral vaccination strategy, with its sturdier
impact on both HPV16 and HPV18, may assist in overcoming the obstacle of suboptimal
girls-only vaccination coverage.
Apart from HPV16 being the most oncogenic HPV type, both dynamic transmission mod-
els and randomized trials have suggested that HPV16 is the most difficult to achieve herd pro-
tection against [14,17]. The vaccination coverage required to achieve herd protection against
a given vaccine-protected type in addition to being strategy-dependent is also population-
dependent [17]. The observation of a degree of partial HPV16 herd effect also in the core
group following gender-neutral vaccination is reassuring, since modeling studies have sug-
gested that the existence of the core group defies creation of herd effect [17]. When using PCR
for the determination of current HPV infections, and concomitant Chlamydia trachomatis
infection as a proxy of sexual risk-taking behavior, only HPV18 herd effect has been observed
among the core group [31]. Whereas the seroprevalence comparisons documented a HPV16
herd effect in those with ‘ever’ core group membership, with HSV-2 seropositivity as the
proxy. Thus, implementing a gender-neutral vaccination strategy is likely to deliver also on
targets of equity in eliminating cervical cancer.
Previously, when following up the 1992–1995 birth cohorts of our community-randomized
trial, no evidence of HPV16 herd effect among unvaccinated females was observed with PCR-
defined endpoints [13]. DNA positivity as identified by one-time PCR-positivity is not a mea-
sure of cumulative infection and is also subject to outcome misclassification owing to its
inability to distinguish persistent infections from transient depositions [32]. The resulting sub-
optimal specificity probably biased the previous estimates of HPV16/18 herd effect [13], and
likely resulted in an underestimation of the true effects.
Sensitivity analyses assuming that serology has imperfect sensitivity to identify cumulative
HPV exposure found that the degree of misclassification was HPV type specific. Furthermore,
the previous validation methods [30] may have underestimated the true specificity. The
remaining misclassification biased the estimates towards the null point. The previously
reported sensitivity estimates were particularly low for HPV18. After quantifying and correct-
ing for this bias, the HPV18 PR estimates were in line with earlier PCR-based observations of
HPV18 herd effect after gender-neutral vaccination [13].
This study is limited by the imperfect ability of HPV serology to identify all cumulative
HPV infection. However, HPV antibodies are a measure of persistent infection, thus by identi-
fying cumulative infection by seroconversion, we identify women with true persistent HPV
infection and exclude the apparent issue of the absence of HPV seroconversion in a proportion
of women who have had only an HPV deposition.
Earlier studies were restricted to the birth cohorts that participated in the community-ran-
domized trial [13]. We now also included females from the unvaccinated birth cohorts, 1996–
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1997, subsequent to the trial cohorts. Because HPV is a sexually transmitted virus, HPV trans-
mission moves in the direction of the older to younger birth cohorts. Thus, the herd effect was
expected to be stronger in the younger vaccinated cohorts [14]. Probably the older vaccinated
male and female 1992–1995 birth cohorts have conferred indirect protection to the subsequent
birth cohorts in the gender-neutral vaccination arm, due to the disruption in HPV transmis-
sion [33].
This is to our knowledge the only serosurvey among unvaccinated females following a com-
munity-randomized trial of different vaccination strategies. A previous serosurvey conducted
in Australia among unvaccinated males to evaluate the first-order herd effect of girls-only vac-
cination found somewhat decreased HPV16/18 seropositivity in its post-vaccination era [34].
However, males seroconvert following HPV infections at lower rates than females, thus result-
ing in a possible underestimation of the true reduction in infection prevalence [35].
This study is strengthened by its utilization of the Finnish infrastructure of population-
based intervention cohorts, biobanks, and registries, linkable via unique personal identifica-
tion numbers. Our extraction of serum samples from all eligible participants in the popula-
tion-based FMC [21] provided a sufficient population-representative sample size to evaluate
vaccination-strategy-specific differences in HPV seroprevalence and account for random
error. Further to this, our sampling of only pregnant females under 23 years at the time of sam-
ple donation captures the age distribution at which the HPV incidence curve peaks and the
demographic most at risk.
This study may be limited in its generalizability, as the average age of mothers at first live
birth in Finland is approximately 29 years [36]. It is possible that our study population of preg-
nant females under 23 years have above-average sexual risk-taking behaviors and lifetime risk
of acquiring HPV. Our results may have incomplete transportability to populations that have
differing baseline risk and sexual network structures This study is also limited to the setting of
moderate vaccination coverage; therefore, the findings are not generalizable to scenarios with
greater vaccination coverage. Furthermore, the findings may also have incomplete generaliz-
ability to a scenario with more consecutively vaccinated birth cohorts and a longer period of
time between vaccination initiation and follow-up. Given our inclusion criteria in this study, it
is also possible that participants may have moved between communities between the com-
mencement of sexual activity and sample donation, which may introduce some bias in our
estimates. However, given that the participants were all pregnant females under the age of 23
years, it is possible that they are the portion of source population that are least likely to move
to a new community.
It may also be possible that changes over time in the sexual network or risk-taking behavior
have altered HPV seroprevalence even in the absence of vaccination. The observed changes in
HSV-2 seroprevalence could conceivably be interpreted as evidence of this. However, HSV-2
epidemiology has globally been undergoing complex changes in recent decades, with HSV-1
increasing and HSV-2 decreasing as the main cause of genital herpes infections [37]. There-
fore, the observed decrease in HSV-2 seropositivity over time is not entirely unexpected and
may be independent of any changes in HPV incidence over the time frame. However, with
respect to this, our study is strengthened by its design, as the within-arm seroprevalence com-
parisons in Arm C, where no HPV vaccination was applied, provided us with a counterfactual
estimate to tackle such possible secular trends.
Our results suggest that when HPV vaccination coverage is moderate, only gender-neutral
vaccination establishes herd effect against HPV16 and HPV18 among unvaccinated females.
This finding supports the implementation of a gender-neutral HPV vaccination policy to
achieve optimal vaccine effectiveness when obtaining a girls-only vaccination coverage of 90%
is impossible.
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